Stockholm, Sweden, August 21, 2026

Implantica AG has announced a major U.S. regulatory milestone after the U.S. Food and Drug Administration (FDA) granted Premarket Approval (PMA) for RefluxStop®, its implant-based treatment for gastroesophageal reflux disease (GERD). The approval enables Implantica to begin preparations for a targeted commercial launch in the United States, expanding access to its technology in the world’s largest medical device market. The milestone follows the FDA’s review of clinical evidence supporting the device’s five-year safety and effectiveness.

FDA Approval Opens U.S. Market for RefluxStop®

The FDA approval represents an important step in Implantica’s development of RefluxStop®, which is designed to treat acid and non-acid reflux by restoring and maintaining the natural anatomy of the gastroesophageal junction. Unlike conventional anti-reflux surgical approaches that can encircle the esophagus or apply pressure to the food passageway, RefluxStop® is designed to maintain the lower esophageal sphincter in its natural physiological position without constricting the esophagus. Implantica said the regulatory decision follows a comprehensive review of the product’s clinical evidence and long-term outcomes. The company now plans to transition from regulatory preparation toward U.S. market execution, initially focusing on selected leading centers and reflux surgeons. The rollout is expected to progress gradually as healthcare professionals receive appropriate training and individual treatment centers become activated.

RefluxStop® Targets GERD Treatment Challenges

GERD is a common chronic condition that can significantly affect quality of life and may require long-term medical or surgical management. According to Implantica, an estimated 78 million people in the United States suffer from acid reflux. RefluxStop® has been developed as an implant-based treatment intended to address the underlying anatomical mechanism contributing to reflux. Conventional anti-reflux surgical procedures may be associated with side effects such as difficulty swallowing, inability to belch or vomit, and gas bloating. Implantica’s technology is intended to provide an alternative surgical approach that does not wrap or constrict the esophagus. The company reports that RefluxStop® already has several years of commercial experience in Europe, with nearly 1,800 patients treated across more than 60 Centers of Excellence in nine European countries. Published five-year clinical outcomes are also cited as supporting the device’s long-term clinical performance.

Advertisement

cGxPJobs Banner

Implantica Prepares for Targeted U.S. Launch

With FDA approval secured, Implantica is focusing on commercial launch activities, physician training, and site activation in the United States. CEO and founder Dr. Peter Forsell described the approval as a defining milestone following years of clinical development, scientific work, and regulatory review. The company intends to establish RefluxStop® initially at selected U.S. centers with experienced reflux surgeons before expanding its commercial footprint. Implantica also continues to develop a broader pipeline of implantable medical technologies, including platforms designed to enable communication, remote monitoring and control of implants, as well as wireless technologies intended to power implantable devices through intact skin. The company said these platforms could potentially support future approaches to remote treatment adjustment and healthcare management. The FDA approval of RefluxStop® marks a significant expansion of Implantica’s medtech presence and creates a new commercial opportunity in the U.S. GERD treatment market.

Source: Implantica press relese